Primary Immunodeficiency Diseases Market by Disease Types (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE Syndrome) and Test Types (Blood and Prenatal Testing), and Treatment Types (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2017-2021

Primary Immunodeficiency Diseases Market by Disease Types (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE Syndrome) and Test Types (Blood and Prenatal Testing), and Treatment Types (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2017-2021

Primary immunodeficiency diseases or disorders (PIDD or PI) are caused as part of the body’s immune system is missing or does not function normally, such that it is an inherited flaw in the immune system that increases the susceptibility to infections. Besides susceptibility to infections, PIDD may cause other health problems as well, including allergies, asthma, swollen joints, digestive tract problems, growth problems or an enlarged liver and spleen. The global primary immunodeficiency disease market is dominated by North America and Europe, collectively accounting for major share of the market in 2015. National PID registries worldwide, increasing healthcare expenditure and  government support are the major factors driving the global primary immunodeficiency diseases market during the forecast period.

The global primary immunodeficiency diseases market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the disease types (antibody deficiency – agammaglobulinaemia, common variable immune deficiency, IgG subclass deficiency, SIgAD; cellular immunodeficiency – Ataxia Telangiectasia, DiGeorge syndrome, hyper IgM syndromes, Wiskott-Aldrich syndrome; innate immune disorders – complement deficiencies, and hyper IgE syndrome) and test types (blood and prenatal testing), treatment types (immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).

The global primary immunodeficiency diseases market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global primary immunodeficiency diseases market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global primary immunodeficiency diseases market and included in this report are Baxter International, Inc., Bio Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB S.A., and Octapharma AG.

Salient Features of the report:
1. Botttom-up research methodology (assumptions) for market size estimation and forecast
2. Global Number of patient population for PID (subtypes) by country, 2013 & 2015
3. Global Number of patient population for treatment or therapy by country, 2013 & 2015
4. Global Number of PID Patients, by 15 Most Commonly Identified PID, 2013 & 2015
5. PID Patient’s Gender and Age – Global Comparative Analysis, 2013 & 2015

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Primary Immunodeficiency Diseases Market

1. Disease Type
1.1. Antibody Deficiency
1.1.1. Agammaglobulinaemia
1.1.2. Common Variable Immune Deficiency
1.1.3. IgG Subclass Deficiency
1.1.4. Selective IgA Deficiency (SIgAD)
1.1.5. Others
1.2. Cellular Immunodeficiency
1.2.1. Ataxia Telangiectasia
1.2.2. DiGeorge Syndrome
1.2.3. Hyper IgM Syndromes
1.2.4. Wiskott-Aldrich Syndrome
1.2.5. Others
1.3. Innate Immune Disorder
1.3.1. Complement Deficiencies
1.3.2. Hyper IgE Syndrome
1.3.3. Others

2. Test Type
2.1. Blood Testing
2.2. Prenatal Testing

3. Treatment Type
3.1. Immunoglobulin Replacement Therapy
3.2. Antibiotics Therapy
3.3. Stem cell and Gene Therapy
3.4. Others

4. Company Profiles
4.1. Baxter International, Inc.
4.2. Bio Products Laboratory
4.3. Biotest AG
4.4. CSL Behring LLC
4.5. Grifols S.A.
4.6. Kedrion S.p.A.
4.7. LFB S.A.
4.8. Octapharma AG

Salient Features of the report:
1. Botttom-up research methodology (assumptions) for market size estimation and forecast
2. Global Number of patient population for PID (subtypes) by country, 2013 & 2015
3. Global Number of patient population for treatment or therapy by country, 2013 & 2015
4. Global Number of PID Patients, by 15 Most Commonly Identified PID, 2013 & 2015
5. PID Patient’s Gender and Age – Global Comparative Analysis, 2013 & 2015

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*